2016
Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers
Ganesh A, Lemongello D, Lee E, Peterson J, McLaughlin BE, Ferre AL, Gillespie GM, Fuchs D, Deeks SG, Hunt PW, Price RW, Spudich SS, Shacklett BL. Immune Activation and HIV-Specific CD8+ T Cells in Cerebrospinal Fluid of HIV Controllers and Noncontrollers. AIDS Research And Human Retroviruses 2016, 32: 791-800. PMID: 27019338, PMCID: PMC4971411, DOI: 10.1089/aid.2015.0313.Peer-Reviewed Original ResearchMeSH KeywordsADP-ribosyl Cyclase 1Anti-HIV AgentsAntiretroviral Therapy, Highly ActiveCD4 Lymphocyte CountCD8-Positive T-LymphocytesDisease ResistanceGene ExpressionHIV InfectionsHIV-1HLA-DR AntigensHost-Pathogen InteractionsHumansLeukocyte Common AntigensLymphocyte ActivationReceptors, CCR5Receptors, CCR7RNA, ViralViral LoadViremiaConceptsCentral nervous systemHIV controllersAntiretroviral therapyT cellsCerebrospinal fluidViral loadCopies/HIV-specific T cellsMajor histocompatibility complex class IActivation markers CD38CSF viral loadHIV-specific CD8Undetectable plasma viremiaExpression of CCR5Majority of HIVPlasma viral loadEffector memory cellsHIV-negative controlsHistocompatibility complex class IAbsence of therapyComplex class ILong-term controlPlasma viremiaElite controllersHIV infection
2015
Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV
Valcour VG, Spudich SS, Sailasuta N, Phanuphak N, Lerdlum S, Fletcher JL, Kroon ED, Jagodzinski LL, Allen IE, Adams CL, Prueksakaew P, Slike BM, Hellmuth JM, Kim JH, Ananworanich J, . Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV. PLOS ONE 2015, 10: e0142600. PMID: 26555069, PMCID: PMC4640512, DOI: 10.1371/journal.pone.0142600.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyStandard combination antiretroviral therapyLog10 HIV RNAAcute HIVCSF cytokinesHIV RNACentral nervous system outcomesIntegrase inhibitorsGamma-induced protein 10Duration of HIVFiebig stages IAcute HIV infectionHIV RNA levelsCNS outcomesAntiretroviral therapyInflammatory markersWeek 24Antiretroviral treatmentHIV infectionPlasma neopterinRandomized armProspective evaluationMean ageHealthy controlsCCR5 antagonistsPhenotypic Correlates of HIV-1 Macrophage Tropism
Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, Schnell G, Sturdevant CB, Kincer LP, Mallewa M, Heyderman RS, Van Rie A, Cohen MS, Spudich S, Price RW, Montefiori DC, Swanstrom R. Phenotypic Correlates of HIV-1 Macrophage Tropism. Journal Of Virology 2015, 89: 11294-11311. PMID: 26339058, PMCID: PMC4645658, DOI: 10.1128/jvi.00946-15.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCD4 AntigensCD4-Positive T-LymphocytesCell Line, TumorHEK293 CellsHIV Envelope Protein gp120HIV Envelope Protein gp160HIV Envelope Protein gp41HIV InfectionsHIV-1HumansMacrophagesReceptors, CCR5Recombinant ProteinsViral TropismVirus InternalizationConceptsT cell-tropic virusesT-tropic virusesMonocyte-derived macrophagesM-tropic virusesMacrophage-tropic virusesV1/V2 regionSoluble CD4Central nervous systemHIV-1Chronic infectionT cellsMacrophage-tropic HIV-1 variantsNervous systemM-tropic HIV-1HIV-1 env geneEnv proteinV2 regionT-cell tropicHIV-1 variantsCD4-bound conformationMacrophage-tropicMacrophage tropismM-tropicSurface CD4CD4
2011
Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy
Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, Fuchs D, Palmer S, Price RW. Raltegravir Treatment Intensification Does Not Alter Cerebrospinal Fluid HIV-1 Infection or Immunoactivation in Subjects on Suppressive Therapy. The Journal Of Infectious Diseases 2011, 204: 1936-1945. PMID: 22021620, PMCID: PMC3209817, DOI: 10.1093/infdis/jir667.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsHIV-1 RNAImmune activationRaltegravir intensificationRNA levelsPlasma human immunodeficiency virus type 1 (HIV-1) RNACSF HIV-1 RNA levelsMedian HIV-1 RNA levelT-cell surface antigen expressionHuman immunodeficiency virus type 1 (HIV-1) RNAOpen-label pilot studySingle-copy assayHIV RNA levelsCerebrospinal fluid infectionHIV-1 infectionCentral nervous systemBaseline viral suppressionSurface antigen expressionT cell activationCSF neopterinIntrathecal immunoactivationSuppressive therapyAntiretroviral therapyTreatment intensificationViral suppressionHIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types
Schnell G, Joseph S, Spudich S, Price RW, Swanstrom R. HIV-1 Replication in the Central Nervous System Occurs in Two Distinct Cell Types. PLOS Pathogens 2011, 7: e1002286. PMID: 22007152, PMCID: PMC3188520, DOI: 10.1371/journal.ppat.1002286.Peer-Reviewed Original ResearchConceptsHIV-1-associated dementiaCentral nervous systemHIV-1 populationsMacrophage-tropic virusesCerebrospinal fluidHuman immunodeficiency virus type 1 (HIV-1) infectionNervous systemCSF of subjectsT cell-tropic virusesViral replicationVirus type 1 infectionType 1 infectionHIV-1 replicationHIV-1 variantsHAD subjectsCNS infectionsTherapy initiationCCR5-tropicOvert dementiaVirological characteristicsNeurocognitive disordersHIV-1Virological stateSurface CD4CSF compartment
2005
HIV-1 Chemokine Coreceptor Utilization in Paired Cerebrospinal Fluid and Plasma Samples: A Survey of Subjects with Viremia
Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, Price RW. HIV-1 Chemokine Coreceptor Utilization in Paired Cerebrospinal Fluid and Plasma Samples: A Survey of Subjects with Viremia. The Journal Of Infectious Diseases 2005, 191: 890-898. PMID: 15717264, DOI: 10.1086/428095.Peer-Reviewed Original ResearchConceptsCerebrospinal fluidImmunodeficiency syndrome dementia complexCD4 T-cell countHuman immunodeficiency virus type 1 (HIV-1) entryMixture of R5Paired Cerebrospinal FluidT-cell countsPlasma samplesSurvey of subjectsHIV-1 populationsAdvanced immunodeficiencyCoreceptor utilizationInhibitor therapyPrincipal coreceptorR5 phenotypeX4 virusesDementia complexR5 virusesR5 tropismChemokine receptorsInfection pathogenesisCell countViral tropismDiscordant tropismCell tropism